VYNE Therapeutics Inc.
NASDAQVYNE Therapeutics just posted Q1 results after market close on May 15 — and the print is the week's defining tension. EPS came in at –$0.08, beating the –$0.18 estimate by ten cents. Revenue of $86,000 missed the $200,000 consensus by more than half. The gap between the beat and the miss captures where the company stands: it's burning less than feared, but generating almost…
Snapshot as of 16 May 2026
VYNE Therapeutics just posted Q1 results after market close on May 15 — and the print is the week's defining tension. EPS came in at –$0.08, beating the –$0.18 estimate by ten cents. Revenue of $86,000 missed the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VYNE — free to start on ORTEX.
Sign up for free →Open VYNE on ORTEX